cyclopropylboronic acid monohydrate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 英文名称: cyclopropylboronic acid monohydrate
• 英文别名: cyclopropylboronic acid;hydrate
• 化学式: C₃H₇BO₂*H₂O
• 分子量: 103.914
• InChiKey: AEYKNXRPKMPNET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  cyclopropylboronic acid monohydrate 、 4-硝基吲唑 在 吡啶 、 copper diacetate 、 sodium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以30 mg的产率得到1-cyclopropyl-4-nitro-1H-indazole
  参考文献：
  名称：

  NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

  摘要：

  公开号：

  EP2589592B1
• 作为试剂：
  描述：

  偶氮二甲酸二叔丁酯 在 cyclopropylboronic acid monohydrate 、 copper(II) acetate monohydrate 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以21%的产率得到二叔丁基叠氮草酸
  参考文献：
  名称：

  Efficient synthesis of cyclopropylhydrazine salts

  摘要：

  An efficient procedure for the synthesis of cyclopropylhydrazine in the form of its salts is reported. The copper salt-catalyzed addition of cyclopropylboronic acid to the azo group of di-tert-butyl azodicarboxylate and subsequent deprotection gave the cyclopropylhydrazine salts in high yields. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2014.05.098

文献信息

• インドール誘導体又はその塩
  申请人：味の素株式会社

  公开号：JP2015166316A

  公开（公告）日：2015-09-24

  【課題】優れたaP2阻害作用を有し、医薬、aP2阻害剤、aP2の阻害により改善される疾患等の治療剤として有用な化合物を提供すること。【解決手段】上記課題は、下記一般式（Ｉ）：［式中の記号は、明細書の定義を参照のこと］で示される化合物またはその塩により解決される。

  提供具有优异的aP2抑制作用的化合物，作为医药、aP2抑制剂、通过aP2抑制改善的疾病等治疗药物的有用性。解决方案是通过以下通用式（I）：[符号的含义请参考说明书]所示的化合物或其盐来解决上述问题。
• DIACYLETHYLENEDIAMINE COMPOUND
  申请人：Kawano Tomoaki

  公开号：US20120046292A1

  公开（公告）日：2012-02-23

  [Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

  【问题】提供一种作为抗肥胖剂有用的化合物。【解决方案】本发明人调查了一种具有DGAT1抑制作用的化合物，该化合物有望成为用于治疗肥胖、2型糖尿病、脂肪肝和与这些疾病相关的疾病的制药组合物的活性成分，结果发现本发明的二酰基乙二胺化合物具有出色的DGAT1抑制作用，从而完成了本发明。也就是说，本发明的二酰基乙二胺化合物具有DGAT1抑制作用，因此可用作预防和/或治疗肥胖、2型糖尿病、脂肪肝和与这些疾病相关的疾病的药剂。
• INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Tatani Kazuya

  公开号：US20120129890A1

  公开（公告）日：2012-05-24

  A compound (I) of the present invention, which has an EP 1 receptor antagonism: [wherein A represents a benzene ring or the like; Y 1 represents a C 1-6 alkylene group; Y 2 represents a single bond or the like; R 1 represents a hydrogen atom, a C 1-6 alkyl group or the like; R 2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group or the like; R 4 represents a hydrogen atom or the like; and R 5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种具有EP1受体拮抗作用的化合物(I)：[其中，A代表苯环或类似物；Y1代表C1-6烷基链；Y2代表单键或类似物；R1代表氢原子、C1-6烷基或类似物；R2代表苯基，该苯基可能具有取代基，也可能为5-成员芳香杂环环或6-成员芳香杂环环，该环可能具有取代基或类似物；R3代表卤原子、C1-6烷氧基或类似物；R4代表氢原子或类似物；R5代表氢原子或类似物]或其药学上可接受的盐。此外，本发明的化合物(I)可用作治疗或预防LUTS，特别是OAB的各种症状的药物。
• Sulphone Compounds and Methods of Making and Using Same
  申请人：Dyke Hazel J.

  公开号：US20130053364A1

  公开（公告）日：2013-02-28

  The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本发明提供了磺酰化合物及其在治疗医学疾病（如肥胖症）中的应用。同时提供了制备各种磺酰化合物的药物组合物和方法。这些化合物被认为对甲硫氨酰肽酶2具有活性。
• Indole derivative or pharmaceutically acceptable salt thereof
  申请人：Tatani Kazuya

  公开号：US08680120B2

  公开（公告）日：2014-03-25

  A compound (I) of the present invention, which has an EP1 receptor antagonism: [wherein A represents a benzene ring or the like; Y1 represents a C1-6 alkylene group; Y2 represents a single bond or the like; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R3 represents a halogen atom, a C1-6 alkoxy group or the like; R4 represents a hydrogen atom or the like; and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明提供了一种具有EP1受体拮抗作用的化合物(I)：[其中，A代表苯环或类似物；Y1代表C1-6烷基；Y2代表单键或类似物；R1代表氢原子，C1-6烷基或类似物；R2代表苯基，可以有取代基，也可以是5-成员芳香族杂环环，可以有取代基，也可以是6-成员芳香族杂环环，可以有取代基或类似物；R3代表卤素原子，C1-6烷氧基或类似物；R4代表氢原子或类似物；R5代表氢原子或类似物]或其药学上可接受的盐。此外，本发明的化合物(I)可以用作治疗或预防下尿路症状，特别是膀胱过度活动症的各种症状的药物。